ADC Therapeutics (ADCT) Cash from Financing Activities (2023 - 2026)

ADC Therapeutics has disclosed Cash from Financing Activities across 4 years of filings, most recently posting -$583000.0 for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$583000.0, down 315.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $150.1 million (up 54.78% YoY), and the FY2025 annual result was $150.9 million, up 55.53% from the prior year.
• Cash from Financing Activities came in at -$583000.0 for Q1 2026 at ADC Therapeutics, down from $57.1 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $98.7 million in Q2 2024 to a low of -$1.1 million in Q4 2024.
• The 4-year median for Cash from Financing Activities is $349000.0 (2023), against an average of $24.7 million.
• Across the five-year window, Cash from Financing Activities plunged 111900.0% in 2024 and jumped 5197.23% in 2025, its largest moves.
• ADC Therapeutics' Cash from Financing Activities stood at -$1000.0 in 2023, then slumped by 111900.0% to -$1.1 million in 2024, then surged by 5197.23% to $57.1 million in 2025, then plunged by 101.02% to -$583000.0 in 2026.
• The last three Cash from Financing Activities figures came in at -$583000.0 (Q1 2026), $57.1 million (Q4 2025), and -$198000.0 (Q3 2025), per Business Quant data.